SCHEMBL2319756

SCHEMBL2319756

COc1ccc(C(O)(C(N)=O)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.54
MEN1 O00255 1/20 0.54
KIF11 P52732 8/20 0.51
CES2 O00748 1/20 0.49
CES1 P23141 1/20 0.49
ALDH1A1 P00352 1/20 0.48
KCNH2 Q12809 1/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
PARP1 P09874 1/20 0.47
PARP10 Q53GL7 1/20 0.47
PARP2 Q9UGN5 1/20 0.47
PARP4 Q9UKK3 1/20 0.47
MAPT P10636 1/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
CDK5 Q00535 1/20 0.45
CDK5R1 Q15078 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28711201 0.86 KMT2A (0.60) KMT2AMEN1KIF11CES2CES1
SCHEMBL2793473 0.86 CYP2C9 (0.58) KMT2AMEN1KIF11CES2CES1
Ethane SCHEMBL3002447 0.83 MAPT (0.59) KMT2AKCNH2PARP1MAPT
SCHEMBL366365 0.83 MAPT (0.58) KMT2APARP1MAPT
SCHEMBL5060670 0.81 KIF11 (0.50) KMT2AMEN1KIF11CES2CES1
SCHEMBL6203510 0.81 CES1 (0.56) KMT2AMEN1KIF11CES2CES1
Hydrochloric Acid SCHEMBL23198120 0.81 MAPT (0.56) KMT2AMEN1PARP1MAPT
SCHEMBL23828851 0.80 KMT2A (0.51) KMT2AMEN1KIF11CES2CES1
SCHEMBL2795435 0.80 CYP2C9 (0.55) KMT2AMEN1CES2CES1ALDH1A1
SCHEMBL17833432 0.79 KCNN4 (0.54) KIF11CES2CES1KCNH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528918-B1 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS NERVIANO MEDICAL SCIENCES SRL (IT) 2014-09-10 EP disclosed
US-8772279-B2 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-07-08 US disclosed
US-20130029974-A1 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-31 US disclosed
EP-2528918-A1 6,7- DIHYDROIMIDAZO [1,5-A]PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS Nerviano Medical Sciences S.r.l. (IT) 2012-12-05 EP disclosed
WO-2011092120-A1 6,7- DIHYDROIMIDAZO [1,5-A] PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-08-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029974-A1 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS MAP3K6, MAP3K1, MAP3K5 KMT2A 1709/4885MEN1 2797/4885KIF11 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.